Business Description
Biohit Oyj
SIC : 3841
ISIN : FI0009005482
Share Class Description:
OHEL:BIOBV: Class BTotal Employee Number:
48Compare
Compare
Traded in other countries / regions
BIOBV.Finland0DRP.UK IPO Date
1999-06-18Description
Biohit Oyj is a Finnish biotechnology company that develops, manufactures, and markets diagnostic tests and other health products, primarily for disorders of the gastrointestinal tract. Its main products include GastroPanel, a blood test that assesses the structure and function of the stomach lining by measuring biomarkers such as pepsinogens and gastrin-17; ColonView, an immunochemical fecal occult blood test for colorectal cancer screening; and Acetium capsules, which bind carcinogenic acetaldehyde in the stomach, particularly for people with acid-free stomachs. The company also produces monoclonal antibodies and analysis systems. Biohit sells its products to healthcare providers, clinical laboratories, and distributors, generating revenue through product sales and licensing. Its largest markets are in Europe and Asia, with a growing presence in other regions.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.07 | |||||
Equity-to-Asset | 0.79 | |||||
Debt-to-Equity | 0.09 | |||||
Debt-to-EBITDA | 0.36 | |||||
Interest Coverage | 35 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 7.03 | |||||
Beneish M-Score | -1.23 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 12.1 | |||||
3-Year EBITDA Growth Rate | 26.2 | |||||
3-Year EPS without NRI Growth Rate | 72.5 | |||||
3-Year Book Growth Rate | 25.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -4.03 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 8.74 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 49.89 | |||||
9-Day RSI | 44.46 | |||||
14-Day RSI | 43 | |||||
3-1 Month Momentum % | 6.07 | |||||
6-1 Month Momentum % | 8.26 | |||||
12-1 Month Momentum % | -5.07 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.31 | |||||
Quick Ratio | 2.09 | |||||
Cash Ratio | 0.91 | |||||
Days Inventory | 60.81 | |||||
Days Sales Outstanding | 65.7 | |||||
Days Payable | 69.48 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.3 | |||||
Shareholder Yield % | -1.3 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 70.19 | |||||
Operating Margin % | 21.74 | |||||
Net Margin % | 19.26 | |||||
EBITDA Margin % | 24.22 | |||||
FCF Margin % | -10.33 | |||||
OCF Margin % | -4.65 | |||||
ROE % | 20.93 | |||||
ROA % | 16 | |||||
ROIC % | 25.53 | |||||
3-Year ROIIC % | 24.08 | |||||
ROC (Joel Greenblatt) % | 132.78 | |||||
ROCE % | 20.71 | |||||
Years of Profitability over Past 10-Year | 5 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 12.2 | |||||
Forward PE Ratio | 14.35 | |||||
PE Ratio without NRI | 10.99 | |||||
Shiller PE Ratio | 269.06 | |||||
PS Ratio | 2.38 | |||||
PB Ratio | 2.28 | |||||
Price-to-Tangible-Book | 2.42 | |||||
EV-to-EBIT | 10.78 | |||||
EV-to-EBITDA | 9.13 | |||||
EV-to-Revenue | 2.22 | |||||
EV-to-FCF | -18.49 | |||||
Price-to-GF-Value | 0.92 | |||||
Price-to-Projected-FCF | 2.84 | |||||
Price-to-Median-PS-Value | 0.61 | |||||
Price-to-Graham-Number | 1.08 | |||||
| Price-to-Net-Current-Asset-Value | 12.2 | |||||
Earnings Yield (Greenblatt) % | 9.28 | |||||
FCF Yield % | -5.38 | |||||
Forward Rate of Return (Yacktman) % | 14.97 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Biohit Oyj Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 16.1 | ||
| EPS (TTM) (€) | 0.199 | ||
| Beta | 0.4272 | ||
| 3-Year Sharpe Ratio | 0.32 | ||
| 3-Year Sortino Ratio | 0.54 | ||
| Volatility % | 39.35 | ||
| 14-Day RSI | 43 | ||
| 14-Day ATR (€) | 0.081379 | ||
| 20-Day SMA (€) | 2.4955 | ||
| 12-1 Month Momentum % | -5.07 | ||
| 52-Week Range (€) | 2.2 - 3.78 | ||
| Shares Outstanding (Mil) | 15.21 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Biohit Oyj Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Biohit Oyj Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-03-18 | In 177 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-11 | In 142 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | 2.68 (-0.37%) | ||
| General meeting for 2026 | 2026-06-03 14:00 | 2.62 (-1.13%) | ||
| Annual report for 2025 | 2026-03-18 | 2.45 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-11 | 3.16 (-5.95%) | ||
| Second quarter earnings results for 2025 | 2025-08-06 09:30 | 3.12 (-1.27%) | ||
| General meeting for 2025 | 2025-06-04 14:00 | 2.80 (+0.00%) | ||
| Annual report for 2024 | 2025-03-19 | 2.88 (-0.35%) | ||
| Fourth quarter earnings results for 2024 | 2025-02-12 09:30 | 3.30 (+0.00%) |
Show
Entries
Biohit Oyj Frequently Asked Questions
What is Biohit Oyj(OHEL:BIOBV)'s stock price today?
The current price of OHEL:BIOBV is €2.44. The 52 week high of OHEL:BIOBV is €3.78 and 52 week low is €2.20.
When is next earnings date of Biohit Oyj(OHEL:BIOBV)?
The next earnings date of Biohit Oyj(OHEL:BIOBV) is 2027-02-11 Est..
Does Biohit Oyj(OHEL:BIOBV) pay dividends? If so, how much?
Biohit Oyj(OHEL:BIOBV) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers